- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04721067
HIV-related Insomnia and Inflammation
Treating Insomnia to Reduce Inflammation in HIV
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Danielle Grounds, RVT
- Phone Number: 317-278-0255
- Email: diground@iu.edu
Study Contact Backup
- Name: Lora Fortenberry, NP
- Phone Number: 317-274-8453
- Email: lfortenb@iu.edu
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Infectious Diseases Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- HIV-1 infection, documented as listed clinically in the participant's electronic medical record by any of the following tests: (1) any licensed rapid HIV test, (2) HIV enzyme test kit at any time prior to study entry, (3) at least one detectable HIV-1 antigen, or (4) at least one detectable plasma HIV-1 RNA viral load.
- Age equal to or greater than 18 years.
- Ongoing receipt of stable antiretroviral therapy of any kind for at least 180 days prior to the date of the HIV-1 RNA value determining eligibility.
- HIV-1 RNA level < 75 copies/mL at Screening.
NOTE: There are no CD4 cell count eligibility criteria for this trial.
-ISI score ≥ 11 at Screening.
NOTE: Use of sleeping aids/medications is permitted as long as the ISI score criterion is met.
Exclusion Criteria:
- Inability to complete written, informed consent.
- Incarceration at the time of any study visit.
- Active suicidality at Entry, as determined by the patient's HIV provider or social worker following a positive response (1, 2, or 3) to PHQ-9 Item #9 and a positive response (yes) to one or more of the three questions (for Question #3, the previous attempt must be within the past 10 years) on the Patient Suicidality Form (see Appendix).
- Diagnosed disease or process, besides HIV infection, associated with increased systemic inflammation (including, but not limited to, systemic lupus erythematosus, inflammatory bowel diseases, or other collagen vascular diseases).
NOTE: Hepatitis B or C co-infections are NOT exclusionary, but treatment for hepatitis C cannot be provided during study participation.
- End stage renal disease requiring renal replacement therapy (dialysis, transplantation).
- Known or suspected malignancy requiring systemic treatment within 180 days of the Entry Visit.
NOTE: Localized treatment for skin cancers is not exclusionary.
-Therapy for serious medical illnesses within 14 days prior to the Entry Visit.
NOTE: Therapy for serious medical illnesses that overlaps with a study visit will result in postponement of that study visit until the course of therapy is completed; postponement outside of the allowed study visit timeframe will result in study discontinuation.
- Pregnancy or breastfeeding during the course of the study.
- Receipt of investigational agents, cytotoxic chemotherapy, systemic immunosuppressive therapies, systemic glucocorticoids (of any dose), or anabolic steroids at the Entry Visit.
NOTE: Physiologic testosterone replacement therapy or topical steroids is not exclusionary. Inhaled/nasal steroids are not exclusionary as long as the participant is not also receiving HIV protease inhibitors.
- Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
- History of bipolar disorder or a psychotic disorder, including schizophrenia.
NOTE: Depressive disorders are not exclusionary.
- Current sleep disorder diagnosis other than insomnia disorder (e.g., sleep apnea).
- Have a schedule requiring a bedtime earlier than 8:00pm or later than 2:00am or arising time earlier than 4:00am or later than 10:00am (thus preventing adoption of SHUTi interventions).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CBT-I
This arm will receive internet CBT-I using SHUTi, a validated and proven therapy provided via internet in the general population.
|
SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones.
It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I.
Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention.
SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation.
Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.
|
Active Comparator: Sleep Education/Hygiene
This arm will receive best practices education on sleep hygiene.
|
A research assistant (RA) will deliver the active control procedures.
During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices.
To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider.
We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in hsCRP levels at 24 weeks
Time Frame: Baseline and 24 weeks
|
Circulating high sensitivity C-reactive protein levels will be measured
|
Baseline and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change is IL-6 levels at 12 and 24 weeks
Time Frame: Baseline, 12 and 24 weeks
|
Circulating interleukin-6 levels will be measured
|
Baseline, 12 and 24 weeks
|
Change is sCD14 levels at 12 and 24 weeks
Time Frame: Baseline, 12 and 24 weeks
|
Circulating soluble CD14 levels will be measured
|
Baseline, 12 and 24 weeks
|
Change in sCD163 levels at 12 and 24 weeks
Time Frame: Baseline,12 and 24 weeks
|
Circulating soluble CD163 levels will be measured
|
Baseline,12 and 24 weeks
|
Change in CD14+CD16+ monocytes at 12 and 24 weeks
Time Frame: Baseline,12 and 24 weeks
|
Circulating intermediate monocytes as defined by flow cytometric evaluation for CD14+CD16+ monocytes will be measured
|
Baseline,12 and 24 weeks
|
Change in hsCRP levels at 12 weeks
Time Frame: Baseline and 12 weeks
|
Circulating high sensitivity C-reactive protein levels will be measured
|
Baseline and 12 weeks
|
Change in Insomnia Severity Index (ISI) at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
ISI questionnaire scores will be measured
|
Baseline, 12, and 24 weeks
|
Change in Pittsburgh Sleep Quality Index (PSQI) at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
PSQI questionnaire scores will be measured
|
Baseline, 12, and 24 weeks
|
Change in Dysfunctional Beliefs and Attitudes about Sleep (DBAS-16) at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
DBAS-16 questionnaire scores will be measured
|
Baseline, 12, and 24 weeks
|
Change in Patient Health Questionnaire-9 (PHQ-9) at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
PHQ-9 questionnaire scores will be measured
|
Baseline, 12, and 24 weeks
|
Change in Hopkins Symptom Checklist (SCL-20) at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
SCL-20 questionnaire scores will be measured
|
Baseline, 12, and 24 weeks
|
Change in Generalized Anxiety Disorder-7 (GAD-7) at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
GAD-7 questionnaire scores will be measured
|
Baseline, 12, and 24 weeks
|
Change in PROMIS Fatigue Short Form at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
PROMIS questionnaire scores will be measured
|
Baseline, 12, and 24 weeks
|
Change in Alcohol Use Disorders Identification Test (AUDIT) at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
AUDIT questionnaire scores will be measured
|
Baseline, 12, and 24 weeks
|
Change in Short Form-36 (SF-36) Health Survey at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
SF-36 questionnaire scores will be measured
|
Baseline, 12, and 24 weeks
|
Change in sleep medication use at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
Concomitant medications for sleep will be recorded
|
Baseline, 12, and 24 weeks
|
Change in insomnia treatment satisfaction at 12 and 24 weeks
Time Frame: Baseline, 12, and 24 weeks
|
Insomnia treatment satisfaction scores will be measured
|
Baseline, 12, and 24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Samir K Gupta, MD, Indiana University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R21MH127206-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
-
Butler HospitalSunovionCompleted
Clinical Trials on SHUTi
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)TerminatedInsomnia | AsthmaUnited States
-
Indiana UniversityCompletedInsomnia | HIV/AIDSUnited States
-
Kaiser PermanenteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingDiabetes Mellitus, Type 2 | Sleep Initiation and Maintenance Disorders | Prediabetic StateUnited States
-
University of VirginiaRecruitingNervous System Diseases | Sleep Disorders, Intrinsic | Dyssomnias | Sleep Wake Disorders | Insomnia | Sleep Initiation and Maintenance Disorders | Cognitive Dysfunction | Alzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Boston UniversityPatient-Centered Outcomes Research InstituteCompleted
-
Norwegian Institute of Public HealthCompleted
-
University of VirginiaCompletedCancer | Insomnia | Sleep Initiation and Maintenance Disorders | Family CaregiversUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedAsthma | Insomnia ChronicUnited States
-
University of VirginiaCompletedCancer | InsomniaUnited States
-
Virginia Commonwealth UniversityMassey Cancer CenterTerminatedCancer | Chronic InsomniaUnited States